OBLN vs. BJDX, INVO, NMRD, QNRX, DYNT, SINT, MOTS, TNON, AEMD, and IONM
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Bluejay Diagnostics (BJDX), INVO Bioscience (INVO), Nemaura Medical (NMRD), Quoin Pharmaceuticals (QNRX), Dynatronics (DYNT), Sintx Technologies (SINT), Motus GI (MOTS), Tenon Medical (TNON), Aethlon Medical (AEMD), and Assure (IONM). These companies are all part of the "medical" sector.
Bluejay Diagnostics (NASDAQ:BJDX) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.
Bluejay Diagnostics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500.
Obalon Therapeutics received 244 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 51.25% of users gave Obalon Therapeutics an outperform vote.
Bluejay Diagnostics has higher earnings, but lower revenue than Obalon Therapeutics.
Bluejay Diagnostics has a net margin of 0.00% compared to Bluejay Diagnostics' net margin of -776.76%. Bluejay Diagnostics' return on equity of -161.38% beat Obalon Therapeutics' return on equity.
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 47.0% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Bluejay Diagnostics had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 0 mentions for Obalon Therapeutics. Obalon Therapeutics' average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.
Summary
Bluejay Diagnostics beats Obalon Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
